Back to basics: tackling the challenges to bedside teaching by Dewji R, Dewji A, Gnanappiragasam D

Get full text

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation... by Plummer, R, Lorigan, P, Steven, N, Scott, L, Middleton, M, Wilson, R, Mulligan, E, Curtin, N, Wang, D, Dewji, R, Abbattista, A, Gallo, J, Calvert, H

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. by Plummer, R, Jones, C, Middleton, M, Wilson, R, Evans, J, Olsen, A, Curtin, N, Boddy, A, McHugh, P, Newell, D, Harris, A, Johnson, P, Steinfeldt, H, Dewji, R, Wang, D, Robson, L, Calvert, H